NasdaqGS:DNLIBiotechs
Denali Therapeutics (DNLI): Revisiting Valuation After Secondary Offering and FDA Priority Review Voucher Progress
Denali Therapeutics (DNLI) just wrapped up a $200 million secondary offering, strengthening its cash position as it talks with the FDA about a potential priority review voucher that could speed key programs.
See our latest analysis for Denali Therapeutics.
The fresh capital raise comes after a choppy stretch, with a 90 day share price return of 26.51 percent but a 1 year total shareholder return of negative 18.79 percent, suggesting momentum is rebuilding from a lower base.
If this financing...